Zetia Cost in Oklahoma 2026: Prices, Insurance, Medicaid, and Compounding Options

What Does Zetia Actually Cost in Oklahoma in 2026?

Oklahoma residents face a wide price range for ezetimibe depending on whether they buy brand or generic, use insurance, or access a compounding pharmacy. Brand Zetia's Merck list price sits near $380 per month, while generic ezetimibe 10 mg tablets at Oklahoma retail pharmacies average roughly $15 per month on a cash-pay basis in 2026. The gap between those two numbers is one of the largest in outpatient cardiology prescribing.

Generic ezetimibe 10 mg became widely available after patent expiration, and the FDA-approved generics carry the same bioequivalence data as the brand. The FDA's Orange Book lists multiple approved ezetimibe 10 mg tablet manufacturers, so supply is not a limiting factor in Oklahoma. Merck's brand Zetia received original FDA approval in 2002, and the labeling documents the 10 mg once-daily dose used in all major outcomes trials.

At Walmart, Costco, and many independent Oklahoma pharmacies, 30 tablets of generic ezetimibe often cost between $12 and $18 without any coupon. Adding a GoodRx or similar discount code can push that below $10 at select locations. The National Library of Medicine's drug pricing transparency resources confirm that generic cholesterol agents represent some of the highest-value substitutions available to patients paying out of pocket.

For patients on a statin-ezetimibe combination, the fixed-dose combination brand Vytorin (simvastatin/ezetimibe) also has generics available, though that product is outside the scope of this Oklahoma-specific cost analysis.

Why Oklahoma Medicaid (SoonerCare) Does Not Cover Zetia

Oklahoma Medicaid, operating under the SoonerCare program, does not include brand Zetia on its Preferred Drug List (PDL) and applies non-preferred or non-covered status to the brand product. SoonerCare does, however, allow prescribers to submit prior authorization requests for non-PDL drugs when a clinical rationale is documented.

The Oklahoma Health Care Authority (OHCA), which administers SoonerCare, publishes its PDL updates quarterly. As of the 2026 formulary cycle, generic ezetimibe has limited preferred status on certain managed care organization (MCO) plans within SoonerCare, so the specific coverage outcome depends on which SoonerCare MCO a patient is enrolled in. Prescribers writing for SoonerCare members should confirm coverage directly with the member's MCO before dispensing.

The ACC/AHA 2019 Guideline on the Primary Prevention of Cardiovascular Disease states: "In patients with LDL-C levels that remain elevated despite maximally tolerated statin therapy, ezetimibe is reasonable as a first add-on agent." That clinical endorsement from a named guideline creates a documented medical necessity basis for prior authorization appeals under SoonerCare.

Patients denied coverage through SoonerCare have two practical routes: the generic cash-pay price of approximately $15 per month, or referral to a licensed 503A compounding pharmacy (discussed below). Neither route requires prior authorization.

The American College of Cardiology's patient cost resource and the AAFP's lipid management guidance both note that generic ezetimibe should be accessible to most patients given its low cash price, even without insurance coverage.

How Generic Ezetimibe Became the Default in Oklahoma

The patent cliff for Zetia created one of the cleaner generic transitions in recent memory. Generics launched in late 2016 after Merck's exclusivity expired, and by 2018 generic ezetimibe had captured the majority of dispensed prescriptions nationally. FDA bioequivalence standards require generics to demonstrate 80 to 125% relative bioavailability compared to the reference listed drug, so clinicians can substitute freely.

The IMPROVE-IT trial, published in the New England Journal of Medicine in 2015, enrolled 18,144 patients with recent acute coronary syndrome and randomized them to simvastatin 40 mg plus ezetimibe 10 mg versus simvastatin 40 mg alone. At a median follow-up of 6 years, the combination reduced the primary composite endpoint (cardiovascular death, nonfatal MI, unstable angina requiring rehospitalization, coronary revascularization, or nonfatal stroke) by 6.4% relative risk reduction, with an absolute risk reduction of 2.0 percentage points (32.7% vs. 34.7%, P<0.001). This trial is the primary evidence base for adding ezetimibe to statin therapy and was the data that cemented guideline-level recommendations for the drug.

Separately, the SHARP trial (N=9,270) examined simvastatin 20 mg plus ezetimibe 10 mg in patients with chronic kidney disease and showed a 17% proportional reduction in major atherosclerotic events (P<0.001), extending the evidence base beyond post-ACS populations.

Oklahoma has roughly 3.96 million residents, and CDC data indicate that approximately 12% of U.S. adults have total cholesterol above 240 mg/dL. That translates to a substantial pool of Oklahoma patients for whom ezetimibe is a clinically appropriate second-line agent after statin optimization.

Compounded Ezetimibe in Oklahoma: Legality and Practical Access

Compounded ezetimibe is legal in Oklahoma when prepared by a licensed 503A pharmacy operating under the federal Drug Quality and Security Act and Oklahoma State Board of Pharmacy regulations. 503A pharmacies compound for individual patients based on a valid prescription from a licensed prescriber. They cannot produce large batches for office stock or general sale, which distinguishes them from 503B outsourcing facilities.

The Oklahoma State Board of Pharmacy licenses and inspects 503A pharmacies operating within the state. A prescriber writing for compounded ezetimibe must document a specific patient need, such as a dye allergy to the commercially available tablet excipients or a need for an alternative dosage form. The FDA's guidance on 503A compounding and USP Chapter 795 standards govern the preparation process.

From a cost standpoint, the raw active pharmaceutical ingredient for ezetimibe is inexpensive at compounding scale, which is why some 503A pharmacies offer compounded ezetimibe preparations at no ingredient charge to the patient (the pharmacy charges a compounding fee that may be covered by the prescribing telehealth or clinical program). This effectively makes the monthly cost $0 for the drug itself in certain clinical arrangements. Patients should confirm licensing status by checking the Oklahoma State Board of Pharmacy's online licensee lookup before filling any compounded prescription.

One practical caution: compounded preparations do not carry FDA approval, meaning the finished product has not undergone the same manufacturing quality review as the commercially approved generic. The FDA's position on compounding vs. approved generics is that when a commercially available FDA-approved generic exists at low cost, compounding is harder to justify on clinical grounds. Oklahoma prescribers should document the specific clinical rationale in the patient chart.

Insurance Coverage for Zetia in Oklahoma: Commercial Plans

Commercial insurance coverage for ezetimibe in Oklahoma depends on the specific formulary tier assigned by each plan. Most commercial formularies in Oklahoma place generic ezetimibe on Tier 1 or Tier 2, with copays ranging from $0 to $30 per month. Brand Zetia is typically placed on Tier 3 or Tier 4 by commercial plans, generating copays of $50 to $200 per month or higher before deductible is met.

The three largest commercial insurers operating in Oklahoma, Blue Cross Blue Shield of Oklahoma, Aetna, and UnitedHealthcare, all maintain formularies where generic ezetimibe has preferred status. CMS guidance on formulary transparency requires Medicare Part D plans to publish their formularies publicly, so patients can compare before enrollment.

Medicare Part D plans available in Oklahoma in 2026 generally cover generic ezetimibe. The Medicare Plan Finder tool allows Oklahoma residents to filter by drug and compare monthly cost-sharing across all Part D plans serving their ZIP code. Because Part D plans change formulary status annually, patients should run this check each October during open enrollment.

For patients whose commercial plan places brand Zetia on a non-preferred tier, Merck offers a copay savings card for commercially insured patients. The Merck savings card can reduce the brand copay to as low as $5 per month for eligible patients. Eligibility excludes patients enrolled in federal programs (Medicaid, Medicare, TRICARE), so SoonerCare members cannot use this card. Details and enrollment are available through the Merck Patient Assistance program page at merck.com.

The AACE/ACE 2022 Lipid Management Guidelines recommend ezetimibe as a first-line add-on therapy in patients not at LDL-C goal on maximally tolerated statin therapy, supporting the medical necessity argument for insurance coverage appeals when a plan denies the drug.

Telehealth Prescribing of Ezetimibe in Oklahoma

Oklahoma allows telehealth prescribing of ezetimibe. The Oklahoma Telemedicine Act and the Oklahoma State Medical Association's telehealth framework permit physicians and advanced practice providers licensed in Oklahoma to establish a valid patient-provider relationship via audio-video telehealth visits and then prescribe Schedule-exempt medications including ezetimibe.

Ezetimibe is not a controlled substance. It is not on any DEA schedule. This means no special DEA registration or in-person visit requirement applies. A telehealth provider can order a baseline lipid panel, review results, and write an ezetimibe prescription entirely remotely. The prescriber must hold a valid Oklahoma medical license or a multistate compact license recognized in Oklahoma.

AHA/ACC guidance supports protocol-based lipid management where the prescribing threshold for adding ezetimibe is an LDL-C at or above 70 mg/dL in very-high-risk patients on maximally tolerated statin therapy. Telehealth platforms that incorporate this threshold into their clinical workflows can identify eligible Oklahoma patients efficiently and without requiring a separate office visit.

The USPSTF statin use recommendation for adults 40 to 75 years old with one or more cardiovascular risk factors and a calculated 10-year cardiovascular event risk of 10% or higher provides the evidence backbone for screening-triggered telehealth outreach. Patients identified through annual wellness visit labs as statin-insufficient can be contacted, enrolled in a telehealth lipid management program, and prescribed ezetimibe without leaving home.

Telehealth prescriptions for ezetimibe in Oklahoma can be sent to any licensed retail or mail-order pharmacy. For patients using a 503A compounding pharmacy, the telehealth prescriber must fax or electronically transmit the compounding-specific prescription with the documented clinical rationale.

Cheapest Ways to Get Ezetimibe in Oklahoma: A Practical Price Ladder

The following price ladder ranks ezetimibe access options in Oklahoma from lowest to highest out-of-pocket cost for a standard 30-day supply of ezetimibe 10 mg.

Tier 1: Compounded ezetimibe via 503A pharmacy with telehealth program ($0 ingredient cost). Available when a licensed Oklahoma 503A pharmacy participates in a clinical program and the prescriber documents medical necessity for the compounded form. Not appropriate for all patients; requires documented rationale.

Tier 2: Generic ezetimibe cash price with discount code ($8 to $15/month). GoodRx, RxSaver, and NeedyMeds all list generic ezetimibe in the $8 to $15 range at Oklahoma pharmacies including Walgreens, CVS, Walmart, and Costco. No insurance required. NeedyMeds maintains a current Oklahoma-specific drug pricing database. The GoodRx price transparency model has been studied in peer-reviewed literature and shown to reduce patient out-of-pocket costs by a mean of 36% versus standard retail price.

Tier 3: Generic ezetimibe through commercial insurance Tier 1 or Tier 2 ($0 to $30/month). Most Oklahoma commercial plans cover generic ezetimibe on preferred tiers. Annual deductible phase may temporarily increase cost. Patients should confirm formulary status before filling.

Tier 4: Brand Zetia with Merck copay savings card ($5/month for eligible commercially insured patients). Only available to commercially insured patients; not usable with SoonerCare or Medicare.

Tier 5: Brand Zetia without savings card ($100 to $380/month depending on insurance tier). This is the least cost-efficient route for virtually every Oklahoma patient. Clinicians prescribing brand Zetia without a copay program in place should confirm the patient's out-of-pocket exposure before the prescription is sent.

The Institute for Clinical and Economic Review (ICER) published an analysis showing that at generic prices, ezetimibe's cost per quality-adjusted life year falls well below the $150,000 willingness-to-pay threshold commonly used in U.S. health economics, making it one of the highest-value cardiovascular drugs available.

Monitoring and Safety Considerations Relevant to Oklahoma Prescribers

Ezetimibe's safety profile is well-documented across more than two decades of clinical use. The most common adverse effects are upper respiratory tract infection, diarrhea, arthralgia, and sinusitis, each occurring in 2 to 4% of patients in the IMPROVE-IT population. The FDA-approved labeling does not require routine laboratory monitoring during ezetimibe therapy, distinguishing it from statins, which carry a liver enzyme monitoring recommendation.

Clinicians should note the rare but documented association between ezetimibe and elevated hepatic transaminases when used in combination with a statin. The Cochrane systematic review of ezetimibe (2018) covering 26 randomized controlled trials found no significant increase in hepatotoxicity, rhabdomyolysis, or cancer risk compared to control, with a pooled relative risk for serious adverse events not statistically different from placebo.

Ezetimibe works by inhibiting the Niemann-Pick C1-Like 1 (NPC1L1) protein in the intestinal brush border, reducing dietary and biliary cholesterol absorption by approximately 50%. This mechanism is distinct from statin-mediated HMG-CoA reductase inhibition, making the combination additive rather than redundant. The average LDL-C reduction from ezetimibe 10 mg monotherapy is 18 to 20%, and when added to a statin, an additional 21 to 27% LDL-C reduction is observed on top of the statin effect, as demonstrated in the SHARP trial data.

For Oklahoma prescribers seeing patients with familial hypercholesterolemia, the FH Foundation clinical guidelines recommend ezetimibe as a standard second-line agent after maximally tolerated statin therapy, with LDL-C targets of <100 mg/dL for heterozygous FH and <70 mg/dL for very-high-risk presentations.

Drug interactions worth noting: ezetimibe is not metabolized by the CYP450 system, which limits pharmacokinetic interactions. Bile acid sequestrants (cholestyramine, colesevelam) reduce ezetimibe absorption by approximately 55%, so these agents should not be taken within 2 hours of ezetimibe if co-prescribed. This interaction is documented in the FDA labeling.

Cyclosporine increases ezetimibe plasma concentrations by a mean of 12-fold, a clinically significant interaction relevant to Oklahoma transplant patients. Prescribers managing post-transplant lipid disorders should review the full interaction profile before initiating ezetimibe in cyclosporine-treated patients. The ACC/AHA 2018 Cholesterol Guideline specifically addresses lipid management in special populations including transplant recipients and recommends reduced doses or alternative agents when significant cyclosporine interaction is anticipated.

LDL-C Targets and When to Add Ezetimibe: Current Guideline Thresholds

The 2018 ACC/AHA Cholesterol Guideline, published in the Journal of the American College of Cardiology, sets the following thresholds for adding ezetimibe after statin therapy:

For very-high-risk ASCVD patients (defined as two or more major ASCVD events, or one major event plus multiple high-risk conditions), the guideline recommends adding ezetimibe if LDL-C remains at or above 70 mg/dL on maximally tolerated statin therapy. The full text states: "For very high-risk patients, if the LDL-C level remains ≥70 mg/dL on maximally tolerated statin therapy, adding ezetimibe is reasonable."

For high-risk primary prevention patients with LDL-C persistently above 100 mg/dL despite statin therapy, the 2019 ACC/AHA Primary Prevention Guideline supports ezetimibe as a first add-on option before considering PCSK9 inhibitors, given the dramatically lower cost.

The European Society of Cardiology/EAS 2019 Dyslipidaemia Guidelines set LDL-C targets of <55 mg/dL for very-high-risk patients and recommend ezetimibe as a second-line therapy in a tiered escalation approach. While European guidelines are not directly binding in U.S. clinical practice, Oklahoma prescribers managing FH or recurrent ACS patients may find the more aggressive ESC targets useful as a clinical reference point.

A 2023 meta-analysis published in JAMA Cardiology examined 14 randomized trials of nonstatin lipid-lowering therapy including ezetimibe and confirmed a log-linear relationship between LDL-C reduction and cardiovascular event reduction, with each 1 mmol/L (approximately 38.6 mg/dL) reduction in LDL-C associated with a 22% reduction in major vascular events regardless of the mechanism used to achieve that reduction. This meta-analytic data reinforces the treatment-target-based approach where ezetimibe is added whenever LDL-C remains above goal on statin alone.